Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Chowell et al.
Nature Medicine
November 2019
Authors and Affiliates
Chowell D1,2, Krishna C3, Pierini F4, Makarov V1,2, Rizvi NA5, Kuo F2, Morris LGT2,6, Riaz N2,7, Lenz TL8, Chan TA9,10,11,12;
1
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Research Group for Evolutionary Immunogenomics, Max Planck Institute for Evolutionary Biology, Plön, Germany.
5
Department of Medicine, Columbia University Medical Center, New York, NY, USA.
6
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
7
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
8
Research Group for Evolutionary Immunogenomics, Max Planck Institute for Evolutionary Biology, Plön, Germany. lenz@post.harvard.edu.
9
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org.
10
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org.
11
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chant@mskcc.org.
12
Weill Cornell School of Medicine, New York, NY, USA. chant@mskcc.org.